| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Inhibition of platelet aggregation induced by platelet-activating factor (PAF) (IC₅₀ ≈ 60 μM) and thrombin (IC₅₀ ≈ 60–80 μM)
Inhibition of P-selectin expression on activated platelets Attenuation of intracellular Ca²⁺ mobilization in PAF-activated platelets Increase in intracellular cAMP levels in platelets[2] |
|---|---|
| ln Vitro |
Curdione preferentially inhibited PAF-induced (0.375 μg/mL) and thrombin-induced (0.3 U/mL) human platelet aggregation in a concentration-dependent manner, with IC₅₀ values around 60–80 μM. It showed much weaker inhibition against ADP-induced (10 μM) and arachidonic acid-induced (0.1 mg/mL) aggregation.
Curdione significantly inhibited P-selectin expression on the surface of PAF-activated platelets in a concentration-dependent manner (40–500 μM). Curdione attenuated the rise in intracellular Ca²⁺ concentration triggered by PAF (0.75 μg/mL) in human washed platelets. Curdione increased intracellular cAMP levels in resting platelets and reversed the decrease in cAMP levels observed in PAF-activated platelets.[2] |
| ln Vivo |
In a carrageenan-induced tail thrombosis mouse model, oral administration of curdione (50, 100, and 200 mg/kg) significantly inhibited thrombus formation in a dose-dependent manner, as measured by reduced relative thrombosis length in the tail. The effect was comparable to that of aspirin (100 mg/kg) used as a positive control.[2]
|
| Cell Assay |
Platelet aggregation was measured turbidimetrically. Human platelet-rich plasma (PRP) was incubated with curdione for 8 minutes at 37°C with stirring, then stimulated with agonists (PAF, thrombin, ADP, or AA). Aggregation was recorded as the change in light transmission, with inhibition calculated relative to control.
P-selectin expression was analyzed by flow cytometry. PRP samples were preincubated with curdione, stimulated with PAF, then stained with fluorescently labeled antibodies against CD41 and CD62p (P-selectin). Intracellular Ca²⁺ concentration was monitored using fura-2/AM-loaded washed platelets. Fluorescence was measured after stimulation with PAF following preincubation with curdione. cAMP levels were measured using a commercial enzyme immunoassay kit. Washed platelets were incubated with curdione, stimulated with PAF, and then processed for cAMP extraction and quantification.[2] |
| Animal Protocol |
A carrageenan-induced tail thrombosis model was used. Male Kunming mice were randomly divided into groups: negative control (10% Tween 80), curdione (50, 100, 200 mg/kg, orally), and positive control (aspirin 100 mg/kg, orally). One hour after administration, mice were subcutaneously injected with 0.1% carrageenan into the back. The ambient temperature was maintained below 17°C to promote thrombosis. At 24 hours post-injection, tail thrombosis length and degree were measured and recorded.[2]
|
| References | |
| Additional Infomation |
Ginger dione is the main sesquiterpene compound isolated from turmeric (Rhizoma wenyujin) essential oil, a traditional Chinese medicine used to promote blood circulation and remove blood stasis. This study reports for the first time the antiplatelet aggregation and antithrombotic activities of ginger dione. Its mechanism of action may include increased cAMP levels, which in turn inhibits intracellular Ca²⁺ mobilization and downregulates P-selectin expression, ultimately inhibiting platelet activation and aggregation. The antithrombotic effect observed in vivo may also be related to enhanced vasodilation. [2]
|
| Molecular Formula |
C15H24O2
|
|---|---|
| Molecular Weight |
236.3499
|
| Exact Mass |
236.177
|
| CAS # |
13657-68-6
|
| PubChem CID |
5362828
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
347.6±42.0 °C at 760 mmHg
|
| Melting Point |
61 - 62 °C
|
| Flash Point |
130.4±24.9 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.458
|
| LogP |
3.12
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
326
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1CC/C=C(\CC(=O)C(CC1=O)C(C)C)/C
|
| InChi Key |
KDPFMRXIVDLQKX-WDZFZDKYSA-N
|
| InChi Code |
InChI=1S/C15H24O2/c1-10(2)13-9-14(16)12(4)7-5-6-11(3)8-15(13)17/h6,10,12-13H,5,7-9H2,1-4H3/b11-6-
|
| Chemical Name |
(6Z)-6,10-dimethyl-3-propan-2-ylcyclodec-6-ene-1,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~423.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (11.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (11.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (11.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2310 mL | 21.1551 mL | 42.3101 mL | |
| 5 mM | 0.8462 mL | 4.2310 mL | 8.4620 mL | |
| 10 mM | 0.4231 mL | 2.1155 mL | 4.2310 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
